Atea Pharmaceuticals (AVIR) Shares Outstanding (Weighted Average) (2019 - 2026)

Atea Pharmaceuticals' Shares Outstanding (Weighted Average) history runs 8 years deep, the most recent figure standing at $79.2 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) fell 7.0% year-over-year to $79.2 million; the TTM figure through Mar 2026 stood at $79.2 million (down 7.0% YoY), while the FY2025 annual figure was $81.5 million, down 3.29% from the prior year.
• Shares Outstanding (Weighted Average) was $79.2 million for Q1 2026 at Atea Pharmaceuticals, down from $81.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $85.2 million in Q1 2025 to a low of $79.1 million in Q3 2025.
• Historically, Shares Outstanding (Weighted Average) has averaged $83.0 million across 5 years, with a median of $83.4 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Weighted Average) rose 1.48% in 2025, then retreated 7.0% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $83.2 million in 2022, then grew by 0.17% to $83.4 million in 2023, then advanced by 1.05% to $84.3 million in 2024, then declined by 3.29% to $81.5 million in 2025, then retreated by 2.82% to $79.2 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $79.2 million (Q1 2026), $81.5 million (Q4 2025), and $79.1 million (Q3 2025), per Business Quant data.